Pelthos Therapeutics (NYSE: PTHS) furnishes Q2 2025 results and program update

Rhea-AI Filing Summary

Pelthos Therapeutics Inc. filed a current report to furnish a press release issued on August 18, 2025. The press release summarizes financial results for the company’s legacy operations for the three and six months ended June 30, 2025 and also provides an update on its therapeutic programs.

The press release is included as Exhibit 99.1, and the company states that this information is being furnished, not filed, under the securities laws, which affects how it is treated for liability and incorporation by reference purposes.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false 0001919246 0001919246 2025-08-18 2025-08-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 18, 2025

Pelthos Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Nevada		001-41964		86-3335449
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4020 Stirrup Creek Drive, Suite 110 Durham, NC		27703
(Address of registrant’s principal executive office)		(Zip code)

Registrant’s telephone number, including area code: (919) 908-2400

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		PTHS		The NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 18, 2025, Pelthos Therapeutics Inc. (the “Company”) issued a press release summarizing its financial results for legacy operations for the three and six months ended June 30, 2025 as well as providing an update on the Company’s therapeutic programs. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.

The information in this Item 2.02 and Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 7.01. Regulation FD Disclosure.

The information disclosed in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is incorporated into this Item 7.01 by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits:

Exhibit No.		Description
99.1		Press Release, dated August 18, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 18, 2025	Pelthos Therapeutics Inc.
	By:	/s/ Francis Knuettel II
		Name:	Francis Knuettel II
		Title:	Chief Financial Officer

FAQ

What did Pelthos Therapeutics Inc. (PTHS) report in this 8-K?

Pelthos Therapeutics Inc. furnished a press release summarizing financial results for its legacy operations for the three and six months ended June 30, 2025, and provided an update on its therapeutic programs.

Which time periods are covered by Pelthos Therapeutics Inc.’s reported results?

The company’s press release covers financial results for its legacy operations for the three and six months ended June 30, 2025.

How is the Pelthos Therapeutics Inc. press release included in the 8-K?

The press release is included as Exhibit 99.1 and is incorporated by reference into Item 2.02 and Item 7.01 of the report.

Is the Pelthos Therapeutics Inc. earnings information considered filed with the SEC?

The company states that the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, under the Securities Exchange Act of 1934.

Does this Pelthos Therapeutics Inc. 8-K mention updates to its therapeutic programs?

Yes. The company notes that the press release includes an update on its therapeutic programs in addition to financial results.

Who signed the Pelthos Therapeutics Inc. 8-K?

The report was signed on behalf of Pelthos Therapeutics Inc. by Francis Knuettel II, the Chief Financial Officer, dated August 18, 2025.